about
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyGenetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy.Clopidogrel "resistance": where are we now?Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointerventionInflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndromeVariability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patientsBoth PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary interventionClopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a reviewFormation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.Personalized antiplatelet therapy for coronary artery disease patients: is this the future?The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.Resistance to aspirin and clopidogrel therapy.Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.Use of cilostazol in percutaneous coronary interventions.P2Y12 receptor: platelet thrombus formation and medical interventions.Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.Clopidogrel resistance: the way forward.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.2-Chloro-ethyl 2-(2-chloro-phen-yl)-2-(4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)acetate.Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis.Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism.Aspirin resistance.Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy.The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects.Thromboembolic complications in patients with clopidogrel resistance after coil embolization for unruptured intracranial aneurysms.Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR).Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease.The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
P2860
Q34019082-91AC86CE-A1A5-4938-A4B2-7F926AD04F1CQ34113879-0D86A69F-C25A-4A05-AFED-5E19D55C0B83Q34212563-145234EE-5979-43A4-BB3B-2CE21CBA0CF1Q34316378-EE7F721C-0131-4E37-9BD9-9C919BE1AC13Q35250401-3DFA6528-2754-4EE0-A011-3B236E9D3E8DQ35691358-9B3DF1F0-313A-4BB1-87E0-3EE2C3A29E4CQ35959359-FA023180-3107-4E90-9ED9-3E64389637F8Q36178772-E513FEFC-A3EE-4596-A70E-6586BAF9F9A3Q36676694-F0E3B1FD-F764-4343-84F1-9E6749DBC622Q36717084-800EF181-7BC1-4D3F-A278-1F35DFD4CBF3Q37550156-10067252-13DD-441F-AB98-96636349A2FBQ37618798-5E162A56-F613-4695-9503-C5CD4948BD27Q37624492-A2EB170C-12B0-4CF4-B6EE-7B9CA1A35BA4Q37642822-39A2DA3C-39A6-45BE-8185-EB7C3EBBDFAEQ37664571-5241B93D-1A66-449D-B3CD-DDD04A1F1107Q37807524-5537B5A8-012F-49CA-8575-51152A6D8D50Q37924998-06626E5F-71EE-4F2C-BF23-DE83386247F2Q38016384-057F6B24-43BD-49E0-A470-A9729505E6E8Q38051192-DFD6F1C6-8AD8-4ED3-91D1-DE43161D31BBQ38056525-7FFE097F-712A-4080-8DB1-C814F9F4E621Q38274517-AE77DD19-AC22-45DC-AA48-5AAEC0E7C238Q38307535-4311DD40-DE90-4A41-8600-D430884CE6C3Q39249688-196506EC-2D6D-485F-B1E8-A0C31021D588Q40225108-338FE4C3-34D7-4C6A-B04E-3CC092589C01Q40366712-82090673-C42E-4E7C-AFFF-8F3FFA534720Q41463098-49B4F374-60E1-493B-BC4F-6D16C364AA20Q41512891-EED6C822-BBE3-427E-9F10-BCE23D67977EQ41651465-44F7CEF4-2895-415F-9952-F78E176A0689Q41751908-E149EA7B-B551-4E38-BACF-E28DAEAF6AC1Q42641720-6E0F855F-75BD-4BD3-A8D0-570AFCA37096Q42952510-91453BCA-FB3E-40BD-B339-FDDC525704D8Q42975065-0D89998F-BA08-4668-8ACE-4C251BA9C245Q43935346-D351AE61-77CA-4B7B-AC1A-98694EAC233BQ44277034-B967417B-133E-4567-AA4D-ADECE05ED58FQ45247864-371CB2E7-7892-4C05-B241-570DE1895AC0Q45937868-CB48449B-C8B4-4AA0-9B08-BED546BAF331Q46355429-20C84D4A-6B14-4FC8-AB90-C5137A7257C3Q46735703-3D50FAE5-C37E-4D20-A2ED-3DA0B88BF20AQ46800789-68E986AF-41F2-446F-B8F0-CB1A19A51320Q46817738-B325053D-8226-4BFE-8FBB-DA7A1788557F
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clopidogrel resistance?
@ast
Clopidogrel resistance?
@en
Clopidogrel resistance?
@nl
type
label
Clopidogrel resistance?
@ast
Clopidogrel resistance?
@en
Clopidogrel resistance?
@nl
prefLabel
Clopidogrel resistance?
@ast
Clopidogrel resistance?
@en
Clopidogrel resistance?
@nl
P1433
P1476
Clopidogrel resistance?
@en
P2093
Paul A Gurbel
Udaya S Tantry
P304
P356
10.1016/J.THROMRES.2006.08.012
P407
P577
2007-01-01T00:00:00Z